Rifkin, R. A., Wu, X., Pereira, B., Gill, B. JA., Merricks, E. M., Michalak, A. J., Goldberg, A. R., Humala, N., Dovas, A., Rai, G., McKhann, G. M., Slesinger, P. A., Canoll, P., & Schevon, C. (2025). A selective small-molecule agonist of G protein-gated inwardly-rectifying potassium channels reduces epileptiform activity in mouse models of tumor-associated and provoked seizures. Neuropharmacology, 265, 110259. https://doi.org/10.1016/j.neuropharm.2024.110259

Loan Nguyen, T. M., Guilloux, J.-P., Defaix, C., Mendez-David, I., Etting, I., Alvarez, J.-C., McGowan, J. C., Highland, J. N., Zanos, P., Lovett, J., Moaddel, R., Corruble, E., David, D. J., Gould, T. D., Denny, C. A., & Gardier, A. M. (2024). Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions. Neuropharmacology, 258, 110065. https://doi.org/10.1016/j.neuropharm.2024.110065

Olson, R. J., Bartlett, L., Sonneborn, A., Milton, R., Bretton-Granatoor, Z., Firdous, A., Harris, A. Z., & Abbas, A. I. (2024). Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI. Neuropharmacology, 257, 110030. https://doi.org/10.1016/j.neuropharm.2024.110030

Chen, B. K., & Denny, C. A. (2023). Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders. Neuropharmacology, 224, 109345. https://doi.org/10.1016/j.neuropharm.2022.109345

Henningfield, J. E., Coe, M. A., Griffiths, R. R., Belouin, S. J., Berger, A., Coker, A. R., Comer, S. D., Heal, D. J., Hendricks, P. S., Nichols, C. D., Sapienza, F., Vocci, F. J., & Zia, F. Z. (2022). Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology, 218, 109220. https://doi.org/10.1016/j.neuropharm.2022.109220

Smith, W. R., & Appelbaum, P. S. (2022). Novel ethical and policy issues in psychiatric uses of psychedelic substances. Neuropharmacology, 216, 109165. https://doi.org/10.1016/j.neuropharm.2022.109165